Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 2, 2008, Pages 623-632

  Bordet, Thierry ^a   Buisson, Bruno ^a,d   Michaud, Magali ^a   Abitbol, Jean Louis ^a   Marchand, Fabien ^b   Grist, John ^b   Andriambeloson, Emile ^c   Malcangio, Marzia ^b   Pruss, Rebecca M ^a  

^a Trophos   (France)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Neurofit   (France)

^d Neuroservice   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLEST 4 EN 3 ONE; GABAPENTIN; MORPHINE; OXIME DERIVATIVE; TRO 19622; VINCRISTINE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHEMOTHERAPY INDUCED NEUROPATHY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SPECIFICITY; EXPERIMENTAL MODEL; MALE; MOTOR NERVE CONDUCTION; NERVE FIBER DEGENERATION; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES;

ANALGESICS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BEHAVIOR, ANIMAL; CHOLESTENONES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; HYPERALGESIA; MALE; NEURAL CONDUCTION; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REACTION TIME; STREPTOZOCIN; VINCRISTINE;

EID: 47949102112     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.139410     Document Type: Article

References (41)

1. Ahlgren SC, Wang JF, and Levine JD (1997) C-fiber mechanical stimulus-response functions are different in inflammatory versus neuropathic hyperalgesia in the rat. Neuroscience 76:285-290.
2. Amir R, Argoff CE, Bennett GJ, Cummins TR, Durieux ME, Gerner P, Gold MS, Porreca F, and Strichartz GR (2006) The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 7:S1-S29.
3. Andriambeloson E, Baillet C, Vitte PA, Garotta G, Dreano M, and Callizot N (2006) Interleukin-6 attenuates the development of experimental diabetes-related neuropathy. Neuropathology 26:32-42.
4. Bennett GJ and Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107.
5. Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P, Akentieva NP, Evers AS, Covey DF, Ostuni MA, et al. (2007) Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 322:709-720.
6. Calcutt NA, Jorge MC, Yaksh TL, and Chaplan SR (1996) Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 68:293-299.
7. Carré M, Andre N, Carles G, Borghi H, Brichese L, Briand C, and Braguer D (2002) Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem 277:33664-33669.
8. Cata JP, Weng HR, Lee BN, Reuben JM, and Dougherty PM (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72:151-169.
9. Chen X and Levine JD (2007) Mechanically-evoked C-fiber activity in painful alcohol and AIDS therapy neuropathy in the rat. Mol Pain 3:5.
10. Courteix C, Eschalier A, and Lavarenne J (1993) Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain 53:81-88.
11. Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, et al. (2004) XP13512 [(±)-1-([(α- Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug. II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 311:324-333.
12. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, et al. (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132:237-251.
13. Evtodienko YV, Teplova VV, Sidash SS, Ichas F, and Mazat JP (1996) Microtubule-active drugs suppress the closure of the permeability transition pore in tumour mitochondria. FEBS Lett 393:86-88.
14. Fernyhough P, Diemel LT, Hardy J, Brewster WJ, Mohiuddin L, and Tomlinson DR (1995) Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 7:1107-1110.
15. Fernyhough P, Diemel LT, and Tomlinson DR (1998) Target tissue production and axonal transport of neurotrophin-3 are reduced in streptozotocin-diabetic rats. Diabetologia 41:300-306.
16. Flatters SJ and Bennett GJ (2006) Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122:245-257.
17. Flatters SJ, Xiao WH, and Bennett GJ (2006) Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 397:219-223.
18. Hanaoka Y, Ohi T, Furukawa S, Furukawa Y, Hayashi K, and Matsukura S (1992) Effect of 4-methylcatechol on sciatic nerve growth factor level and motor nerve conduction velocity in experimental diabetic neuropathic process in rats. Exp Neurol 115:292-296.
19. Hanaoka Y, Ohi T, Furukawa S, Furukawa Y, Hayashi K, and Matsukura S (1994) The therapeutic effects of 4-methylcatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental diabetic neuropathy in rats. J Neurol Sci 122:28-32.
20. Hellweg R, Raivich G, Hartung HD, Hock C, and Kreutzberg GW (1994) Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 130:24-30.
21. Hong S, Morrow TJ, Paulson PE, Isom LL, and Wiley JW (2004) Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem 279:29341-29350.
22. Jin HW, Flatters SJ, Xiao WH, Mulhern HL, and Bennett GJ (2008) Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol 210:229-237.
23. Joseph EK, Chen X, Khasar SG, and Levine JD (2004) Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 107:147-158.
24. Kleinschnitz C, Brinkhoff J, Zelenka M, Sommer C, and Stoll G (2004) The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol 149:77-83.
25. Leinninger GM, Edwards JL, Lipshaw MJ, and Feldman EL (2006) Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol 2:620-628.
26. Lowell BB and Shulman GI (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307:384-387.
27. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, and Myers RR (2002) Injury type-specific calcium channel α2 δ-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 303:1199-1205.
28. Malcangio M and Tomlinson DR (1998) A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 76:151-157.
29. Mizisin AP, Calcutt NA, Tomlinson DR, Gallagher A, and Fernyhough P (1999) Neurotrophin-3 reverses nerve conduction velocity deficits in streptozotocin-diabetic rats. J Peripher Nerv Syst 4:211-221.
30. Moalem G and Tracey DJ (2006) Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 51:240-264.
31. Pastorino JG, Snyder JW, Serroni A, Hoek JB, and Farber JL (1993) Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. J Biol Chem 268:13791-13798.
32. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, et al. (2003) Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 9:5756-5767.
33. Said G (2007) Diabetic neuropathy - a review. Nat Clin Pract Neurol 3:331-340.
34. Shigenaga MK, Hagen TM, and Ames BN (1994) Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A 91:10771-10778.
35. Siau C and Bennett GJ (2006) Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 102:1485-1490.
36. Siau C, Xiao W, and Bennett GJ (2006) Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 201:507-514.
37. Thant M, Hawley RJ, Smith MT, Cohen MH, Minna JD, Bunn PA, Ihde DC, West W, and Matthews MJ (1982) Possible enhancement of vincristine neuropathy by VP-16. Cancer 49:859-864.
38. Tomlinson DR and Gardiner NJ (2008) Glucose neurotoxicity. Nat Rev Neurosci 9:36-45.
39. Vincent AM, Russell JW, Low P, and Feldman EL (2004) Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 25:612-628.
40. Visovsky C (2003) Chemotherapy-induced peripheral neuropathy. Cancer Invest 21:439-451.
41. Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110.